Written By: Adam Pick, Patient Advocate, Author & Website Founder
Published: May 3, 2026
I just heard from Dr. Lars Svensson, Chief of the Heart, Vascular and Thoracic Institute at the Cleveland Clinic, that the updated results of the COMMENCE trial just were shared at the American Association for Thoracic Surgery Conference that is happening right now in Chicago, Illinois.
INSPIRIS RESILIA Tissue Valve Studied in COMMENCE Trial
Dr. Svensson shared, “I just had the privilege of presenting the COMMENCE Trial results at AATS. The 10-year data is encouraging, showing low rates of structural valve deterioration and reoperation, even in younger patients who typically face higher risks. This tissue technology could reshape how we think about biological valve durability. Long-term evidence matters.”
Presented the COMMENCE Trial at #AATS2026 – the 10 yr data is encouraging, showing low rates of structural valve deterioration & reoperation, even in younger pts who typically face higher risks.
This tissue technology could reshape how we think about biological valve durability. pic.twitter.com/IBBuZrl2Dw
— Lars Svensson (@LarsSvenssonMD) May 2, 2026
Thanks to Dr. Svensson for letting me know about these late-breaking clinical trial results for the COMMENCE study!
Related Links:
Keep on tickin!
Adam
